Voyager Therapeutics, Inc. financial data

Symbol
VYGR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
75 Hayden Avenue, Lexington, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 670 % +37.7%
Debt-to-equity 35.4 % -49.3%
Return On Equity 8.33 % -74.1%
Return On Assets 6.15 % -67.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.6M shares +24.2%
Common Stock, Shares, Outstanding 54.5M shares +24.2%
Entity Public Float 489M USD +330%
Common Stock, Value, Issued 55K USD +25%
Weighted Average Number of Shares Outstanding, Basic 57.9M shares +31.9%
Weighted Average Number of Shares Outstanding, Diluted 57.9M shares +31.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 64.3M USD -59.4%
Research and Development Expense 118M USD +45.2%
General and Administrative Expense 37.2M USD +9.18%
Operating Income (Loss) 9.08M USD -79.1%
Nonoperating Income (Expense) 17.7M USD +86%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 26.8M USD -49.4%
Income Tax Expense (Benefit) 903K USD
Net Income (Loss) Attributable to Parent 25.9M USD -50.5%
Earnings Per Share, Basic 0.59 USD/shares -56%
Earnings Per Share, Diluted 0.59 USD/shares -52.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 113M USD +72.4%
Marketable Securities, Current 233M USD +24.1%
Cash, Cash Equivalents, and Short-term Investments 345M USD +36.6%
Other Assets, Current 2.63M USD -37.9%
Assets, Current 373M USD +42.6%
Property, Plant and Equipment, Net 15.2M USD -11.2%
Operating Lease, Right-of-Use Asset 34.5M USD +146%
Assets 426M USD +44.6%
Accounts Payable, Current 3.16M USD -3.36%
Employee-related Liabilities, Current 5.93M USD +23.2%
Accrued Liabilities, Current 11.4M USD +3.54%
Contract with Customer, Liability, Current 22.6M USD -48.9%
Liabilities, Current 44.2M USD -28.3%
Contract with Customer, Liability, Noncurrent 12.2M USD -67.9%
Operating Lease, Liability, Noncurrent 38.4M USD +114%
Other Liabilities, Noncurrent 39.4M USD +108%
Liabilities 95.7M USD -19.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -33K USD +86.7%
Retained Earnings (Accumulated Deficit) -292M USD +8.15%
Stockholders' Equity Attributable to Parent 330M USD +87.4%
Liabilities and Equity 426M USD +44.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 58.8M USD -52.4%
Net Cash Provided by (Used in) Financing Activities 113M USD +260%
Net Cash Provided by (Used in) Investing Activities -96.1M USD -763%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54.5M shares +24.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 75.6M USD -55.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 115M USD +72.6%
Deferred Tax Assets, Valuation Allowance 82.6M USD -29.6%
Deferred Tax Assets, Gross 89M USD -28.7%
Depreciation 1.2M USD +11.3%
Payments to Acquire Property, Plant, and Equipment 2.14M USD +321%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 26.1M USD -50.2%
Property, Plant and Equipment, Gross 31.5M USD -10.1%
Operating Lease, Liability, Current 6.98M USD +125%
Deferred Tax Assets, Operating Loss Carryforwards 13.7M USD -71%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 622M USD +25.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.43M USD -13.4%
Share-based Payment Arrangement, Expense 14.1M USD +34.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%